Zenith Health Care Ltd
Incorporated in 1993, Zenith Healthcare Ltd is engaged in trading and manufacturing of pharmaceutical products.
- Market Cap ₹ 23.6 Cr.
- Current Price ₹ 4.40
- High / Low ₹ 6.87 / 3.82
- Stock P/E 338
- Book Value ₹ 1.38
- Dividend Yield 0.00 %
- ROCE 3.93 %
- ROE 0.95 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.20 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -1.11% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 1.60% over last 3 years.
- Debtor days have increased from 64.3 to 78.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3.27 | 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 11.33 | |
3.54 | 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.24 | 11.24 | |
Operating Profit | -0.27 | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.23 | 0.09 |
OPM % | -8.26% | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.59% | 0.79% |
0.10 | 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.27 | 0.43 | |
Interest | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Depreciation | 0.24 | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.23 |
Profit before tax | -0.41 | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.28 |
Tax % | -31.71% | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | 78.57% |
-0.27 | -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.07 | |
EPS in Rs | -0.05 | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.01 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | -1% |
3 Years: | -20% |
TTM: | -22% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | -34% |
3 Years: | -39% |
TTM: | -65% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 17% |
3 Years: | -9% |
1 Year: | 2% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 3% |
3 Years: | 2% |
Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
Reserves | 0.68 | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.03 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.78 | 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.42 | 3.48 | |
Total Liabilities | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.75 | 10.88 |
1.37 | 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.55 | |
CWIP | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
4.67 | 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.35 | 9.33 | |
Total Assets | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.75 | 10.88 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.07 | 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | 0.67 | |
-0.44 | -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -0.11 | -1.09 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | -0.51 | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | 1.63 | -0.41 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 218.78 | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 50.70 | 77.96 |
Inventory Days | 192.90 | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 91.25 | 152.87 |
Days Payable | 132.38 | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 33.64 | 91.59 |
Cash Conversion Cycle | 279.29 | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 108.31 | 139.24 |
Working Capital Days | 296.91 | 246.68 | 208.87 | 136.40 | 82.13 | 96.91 | 48.14 | 98.02 | 50.93 | 116.76 | 59.03 | 69.59 |
ROCE % | -6.79% | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% | 3.93% |
Documents
Announcements
-
Closure of Trading Window
25 Jun - Trading window closed from July 1, 2025, till 48 hours post Q1 results announcement.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - Paper Cuttings of Published Audited Finacial Results for the Quarter and Year ended 31st March, 2025
-
Appointment Of Kamlesh M. Shah & Co. Company Secretaries As A Secretarial Auditors For A Period Of Five Years.
28 May - Appointment of Kamlesh M. Shah & Co. as secretarial auditor for five years from 2025 to 2030.
-
Appointment Of M/S. Mohta Khetawat & Co., Chartered Accountants As A Inetrnal Auditor And Kamlesh M. Shah & Co. , Company Secretaries As A Secretarial Auditors For A Period Of Five Years.
27 May - Audited FY25 results approved; net profit Rs.6.7L; new internal auditor appointed; unmodified audit opinion.
-
Financial Result For F.Y. 2024-25.
27 May - Zenith Healthcare approved audited FY25 results; net profit Rs.6.70L; appointed internal auditor; unmodified audit opinion.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1]
a) Pharmaceutical Pills: Alprazolam & Propranolol HCL Tablets, Pantoprazole Sodium Levosulpiride Capsules, Vicadol, Mdzime
b) Pharmaceutical Syrup And Protein Powder: Azithromycin Dihydrate Suspension, Cofzen Syrup, Domperidone Suspension, Zenoset Syrup, Valprex Syrup
c) Oral Rehydration Salt: Albendazole Oral Suspension, Erythromycin Oral Suspension
d) Sertraline Tablets: Alprazolam & Sertraline Tablets
e) Antipsychotic: Loxapine Drops
f) Omeprazole Capsules